Back to mobile site
Get it on Google Play

EU panel backs Acadia's Rett syndrome drug trofinetide for approval

June 26, 2026 6:49 AM EDT Send to a Friend
Acadia Pharmaceuticals (NASDAQ: ACAD) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login